Supernus CEO Jack Khattar Exercises Awards, Sells Shares for Taxes

What Happened Jack A. Khattar, President, CEO and a director of Supernus Pharmaceuticals (SUPN), had 29,849 performance-based derivative awards convert into common stock on 2026-08-12. The company withheld 12,642 of those shares to satisfy $588,738 in tax withholding, leaving a net of 17,207 shares retained by Mr. Khattar. The filing shows the conversion/exercise reported under code M and the withholding reported under code F.

Key Details

• Transaction date: August 12, 2026; Form 4 filed August 14, 2026 (timely filing).
• Conversion/exercise: 29,849 shares @ $0.00 (code M — Performance Share Units converted).
• Tax withholding/disposition: 12,642 shares @ $46.57 = $588,738 (code F — shares withheld to satisfy tax).
• Net shares retained from the vesting/conversion: 29,849 − 12,642 = 17,207 shares.
• Footnotes: F1 confirms withheld shares were used to satisfy tax withholding on PSUs; F2 notes the PSUs were awarded Feb 19, 2025, with vesting tied to individual performance objectives established May 3, 2025.
• Shares owned after transaction: Not specified in the provided filing.

Context This was an award vesting/conversion and a routine company withholding of shares to cover tax liabilities (a form of cashless/net settlement), not an open-market sale by the insider. Such tax-withholding dispositions are common and do not necessarily indicate a change in the insider’s view of the company.